Eli Lil­ly’s flag­ship obe­si­ty med­ica­tions will be in­clud­ed in CVS Care­mark for­mu­la­ries, like­ly boost­ing sales in the most com­pet­i­tive com­mer­cial drug mar­ket.

The com­pa­ny an­nounced...

Three months ago, Charles Riv­er Lab­o­ra­to­ries an­nounced it would shed its man­u­fac­tur­ing unit, which has a fo­cus on cell and gene ther­a­pies. And, ac­cord­ing to...

Ab­b­Vie said the FDA has ap­proved an an­ti­body-drug con­ju­gate it ob­tained as a part of its $10.1 bil­lionbuy­out of Im­muno­Gen for an ul­tra-rare but...

GSK has shared de­tailed re­sults from a pair of late-stage tri­als test­ing a chron­ic he­pati­tis B treat­ment orig­i­nal­ly de­vel­oped by Io­n­is Phar­ma­ceu­ti­cals, with reg­u­la­to­ry re­views...

👀 ICON’s au­dit probe is com­plete: The in­ves­ti­ga­tion found that ICON’s rev­enue was over­stat­ed by $65.3 mil­lion in 2023 (about 0.8% of its to­tal rev­enue...